Amplexd Therapeutics Initiates Phase 2 Clinical Trial of Investigational EGCg-Based HPV TherapyGAITHERSBURG, Md., May 19, 2026 (GLOBE NEWSWIRE) -- Amplexd Therapeutics, Inc. (“Amplexd”), a U.S.-based clinical-stage biotechnology company focused on women’s health and underserved therapeutic areas, today announced authorization from the Hong Kong Department of Health to initiate a Phase 2 clinical trial evaluating its novel EGCg-based investigational therapy for precancerous cervical lesions associated with high-risk human papillomavirus (hr-HPV).
